9 recruiting, 4 completed, 4 terminated, 2 active not recruiting. 16 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Recruiting 8, Completed 3, Terminated 3, Active not recruiting 2 |
| Phase 2 | 9 | Recruiting 4, Terminated 3, Completed 2 |
Follow Refractory Chronic Myelomonocytic Leukemia: new trials by email Literature Review of Refractory Chronic Myelomonocytic Leukemia trials Research Report on Refractory Chronic Myelomonocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) STX-0712 - Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Recruiting | Solu Therapeutics, Inc | 105 | 2025-03-13 | 2026-02-09 |
| Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia Axatilimab, Azacitidine, Biospecimen Collection - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Uma Borate | 49 | 2024-08-02 | 2026-08-27 |
| Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Onvansertib - Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 25 | 2023-04-04 | 2026-06-22 |
| Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents Fostamatinib - Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome | Phase 1 | Completed | M.D. Anderson Cancer Center | 11 | 2021-08-13 | 2025-02-13 |
| FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies FHD-286, Low Dose Cytarabine, Decitabine - Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia | Phase 1 | Active not recruiting | Foghorn Therapeutics Inc. | 144 | 2021-06-14 | 2025-07-10 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia Cladribine, Cyclophosphamide, Cyclosporine - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 120 | 2020-12-03 | 2026-09-17 |
| Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Azacitidine, Venetoclax - Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 34 | 2020-09-04 | 2026-06-05 |
| A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Canakinumab - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 76 | 2020-08-25 | 2026-05-20 |
| Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome Azacitidine, Trametinib, Venetoclax - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 21 | 2020-07-21 | 2025-04-22 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm Azacitidine, Gilteritinib, Venetoclax - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 97 | 2019-12-17 | 2026-10-06 |
| CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Liposome-encapsulated Daunorubicin-Cytarabine - Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 38 | 2019-05-14 | 2026-10-06 |
| A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies PRT543 - Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 | Completed | Prelude Therapeutics Incorporated | 232 | 2019-02-11 | 2023-03-28 |
| Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 72 | 2019-01-31 | 2026-09-18 |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome Decitabine, Laboratory Biomarker Analysis, Venetoclax - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Terminated | M.D. Anderson Cancer Center | 235 | 2018-01-18 | 2026-03-10 |
| Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Azacitidine, Cytarabine, Quizartinib - FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 73 | 2013-11-12 | 2025-04-06 |
Leukemia, Myelomonocytic, Chronic (19) · Leukemia, Myeloid, Acute (12) · Myelodysplastic Syndromes (12) · Myelodysplastic-Myeloproliferative Diseases (4) · Primary Myelofibrosis (4) · Hematologic Neoplasms (3) · Leukemia, Biphenotypic, Acute (3) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (3) · Myeloproliferative Disorders (3) · Blast Crisis (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia (1) · Anemia, Refractory, with Excess of Blasts (1)
Bone Marrow Diseases (19) · Chronic Disease (19) · Disease Attributes (19) · Hematologic Diseases (19) · Hemic and Lymphatic Diseases (19) · Leukemia (19) · Leukemia, Myeloid (19) · Neoplasms (19) · Neoplasms by Histologic Type (19) · Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Myelodysplastic-Myeloproliferative Diseases (15) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7)
Azacitidine (6) · Cytarabine (6) · venetoclax (6) · Specimen Handling (5) · Biopsy (4) · Decitabine (3) · Filgrastim (3) · Granulocyte Colony-Stimulating Factor (3) · Injections (3) · Cyclophosphamide (2) · Hematopoietic Stem Cell Transplantation (2) · Idarubicin (2) · Leucovorin (2) · Stem Cell Transplantation (2) · Whole-Body Irradiation (2)
M.D. Anderson Cancer Center (10) · Fred Hutchinson Cancer Center (2) · Mayo Clinic (2) · Foghorn Therapeutics Inc. (1) · OHSU Knight Cancer Institute (1) · Prelude Therapeutics Incorporated (1) · Solu Therapeutics, Inc (1) · Uma Borate (1)
United States (19)
Guillermo Garcia-Manero (2) · Guillermo M Bravo (2) · Nicholas Short (2) · Abhishek Maiti, MBBS (1) · Filippo Milano (1) · Jithma P. Abeykoon, MD (1) · Lara Davis, MD (1) · Mrinal S. Patnaik, MBBS (1) · Naval G Daver, MD (1) · Naveed Ali, MD (1) · Sarah Reilly, MD (1) · Tapan M Kadia (1) · Uma M Borate, MD (1) · Yesid Alvarado, MD (1)
PMID 32896301, PMID 33027528, PMID 33580980, PMID 33792630, PMID 34255353, PMID 34474640, PMID 36841758, PMID 37946611, PMID 38118249, PMID 38277619, PMID 39537648, PMID 39863139, PMID 40238563, PMID 42013378, PMID 42200455
P30CA015704 (1), P50CA100632 (1), R01CA272496 (1)